Grant Search

Cancer Type

Keyword Search  

Categories

Grant Amount
>=

<=





Results: 269

Intranasal Delivery of Targeting Nanotherapeutics for DIPG

Pediatric gliomas are one of the most common cause of cancer-related death in children, and diffuse intrinsic pontine gliomas (DIPGs) are the most rapidly fatal of these tumors. No significant advances in the survival of patients with DIPG have been made over the last few decades, and new therapeutic approaches ...

Targeting diffuse midline gliomas with innovative T cell immunotherapy

Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPG), are highly aggressive brain tumors that mainly affect children and currently have no cure. Traditional treatments like chemotherapy and radiation have limited success, leaving an urgent need for new therapies to improve survival rates while minimizing side effects. Chimeric antigen ...

Clinical development of the novel immunotoxin, GB13, for the treatment ...

Diffuse Intrinsic Pontine Glioma (DIPG) is a rare, pediatric tumor typically arising in the brainstem with no effective treatment options. Every year approximately 400 children in the US are diagnosed with this disease. Physical location, the blood-brain barrier and limited characterization of DIPG have played key roles in the inability ...

Controlling DIPG/DMG with the protein kinase C-iota inhibitor ICA-1...

Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG) are currently incurable childhood brain tumors. Elucidating the regulation of signaling pathways in pediatric DIPG and DMG is critical to targeting tumor cell migration and spreading.  Until these pathways are understood, comprehensive and effective treatment of this group ...

EphB3 controls DIPG invasion via regulation of glioma-to-neuron synaptogenesis

Diffuse Intrinsic Pontine Glioma (DIPG), is a highly aggressive, universally fatal brain stem glioma arising in young children.1 There are no effective therapies for DIPG and children typically succumb to the disease within two years of diagnosis.2 Previous studies have shown that DIPG tumours actively communicate with neurons, a phenomenon ...

Development of the next generation immunotherapy for diffuse midline gliomas

Diffuse intrinsic pontine glioma (DIPG) is the most aggressive brain tumour in children. Every year, about 150-300 children in the USA and 3,000 children worldwide are diagnosed with DIPG. The prognosis of DIPG is devastating as only 10% of the patients will live for more than two years1,2. In the ...